A neuropsychological test battery for use in Alzheimer disease clinical trials.
about
Omega-3 fatty acids for the treatment of dementiaSouvenaid for Alzheimer's diseaseMetal protein attenuating compounds for the treatment of Alzheimer's dementiaMetal protein attenuating compounds for the treatment of Alzheimer's dementiaCognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB.Normative and standardized data for cognitive measures in the Mexican Health and Aging Study.Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?Assessment of cognition in mild cognitive impairment: a comparative studyRandomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.Controversies in Alzheimer's disease drug developmentTwo phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.Recruitment and baseline characteristics of participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)-a randomized controlled lifestyle trialClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's diseaseEstablishing robust cognitive dimensions for characterization and differentiation of patients with Alzheimer's disease, mild cognitive impairment, frontotemporal dementia and depression.How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: a statement from the International Academy on Nutrition and Aging Task Force.A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseCurrent Alzheimer's disease clinical trials: methods and placebo outcomes.Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review.Advances in designs for Alzheimer's disease clinical trials.Modeling the course of Alzheimer's disease to improve clinical trials: symposium reportEarly BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic miceTargeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trialsClinical trial design issues in mild to moderate Alzheimer disease.Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery diseaseA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease.Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition.Cardiorespiratory fitness and brain volumes in men and women in the FINGER study.Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial.A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study.Souvenaid®: a new approach to management of early Alzheimer's disease.Improving the accuracy and precision of cognitive testing in mild dementia.
P2860
Q24185910-13D2425E-76C9-47D9-92E5-4CA966D3FB98Q24188326-850FA3C3-7A10-41C5-B28C-CCEB2B1A2B19Q24197913-045A8D3C-6328-47B7-A11B-0EAA81CB0370Q24200310-9F5F8373-372E-45B6-AA92-E26958424E88Q30755701-CD29B7A2-0CFE-46F8-812F-C9DFB35A7B9FQ30980263-17FAE36E-F8F2-416A-A8A9-C10B8D270E0EQ33460503-7FB2874B-37E8-4261-8927-AF12C4E0FE1CQ33674688-5D9B8D7D-E8D7-4682-A3B8-5DD113324C82Q33675522-1FA96F5D-E597-4389-87E9-01ED6219A915Q33703851-910D7938-7998-4AB6-91A6-724139BFA7C3Q33736797-A94AB3D9-36FB-4743-A922-86FCE5214ADCQ33805090-B30EAF09-87D7-401B-88C9-B484E2BBA75EQ34157492-BED35806-ACD9-4801-B5A4-1DC9A52C1931Q34348190-D22BC6F9-7AFF-438E-A51A-829325DD9F7CQ34408888-A54CDFE5-8EDE-4E32-9895-E8141081424EQ34533985-DD9D0CB1-B4C6-4928-920C-566439EF2B54Q34692886-FEBF895E-7750-4B66-AF82-EAAB03B8AC12Q35034114-BF94CD36-9E1C-478C-A2E1-06661BE88460Q35230963-6573BA9B-7FEB-471E-8AB0-59931DAE4A91Q35876532-BC7D5ED5-A8DE-421E-86AE-DBA1D8DD86DBQ36022784-3B29E766-84AA-4311-83D9-41242E5D6FDAQ36274037-3C16CF3C-8358-4933-BD8A-EF3B04429BE6Q36334769-D331C6C6-748D-4D51-8BF8-15BF48AEA8BFQ36361642-66F16E05-98C2-45F0-AC00-1879B2D1C4EFQ36576472-ABAD8011-4965-4F3E-82EE-B416B1D638CBQ36998328-F0CDD61F-7E8B-47E3-A658-72CD02841126Q37196325-9EA4BCF4-DB49-4173-9E30-8DB02DC2CE63Q37215851-45ABDE15-2975-4443-95FE-F814145BE959Q37235850-8919D7D2-F2D2-4A6C-B9AE-4CC5D8610EADQ37341400-1DAFCE88-A2FC-471B-BC13-BEABD6A2529AQ37413053-4EABFBA3-85B3-4A78-9861-70B27FE4EBF8Q37465017-0E451608-0198-4D96-9BA4-AC17EA68226AQ37489106-312CF467-ED42-45A6-8BA1-0A2F4C17B9B9Q38286246-A3A2443C-4814-4870-98BD-8D3B888874BAQ38697144-F8A3DC05-D0BB-4AB4-9EAF-8EAC6EDD37E5Q39033967-B156C8C9-450E-4DA6-A8EB-43B687B47E80Q42218743-5CB771B2-53FA-41ED-A467-9E8047E4B924Q42656112-193FAC1B-70FF-482D-A6FB-07839039F381Q43864462-DCD8919D-5B18-49A3-8EC0-CDD0761ACD0AQ46074461-6D38F99E-BE1B-4E5E-8366-201F6BB0A8DE
P2860
A neuropsychological test battery for use in Alzheimer disease clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@en
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@nl
type
label
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@en
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@nl
prefLabel
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@en
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@nl
P2093
P1433
P1476
A neuropsychological test battery for use in Alzheimer disease clinical trials.
@en
P2093
John Harrison
Lisa Jenkins
Martin Koller
Michael Grundman
Ronald S Black
Sonia L Minassian
P304
P356
10.1001/ARCHNEUR.64.9.1323
P577
2007-09-01T00:00:00Z